Cart is empty Currently, half of patients with non-Hodgkin’s lymphoma and acute lymphoblastic leukemia—two types of cancer that affect blood cells—do not respond adequately to treatment with CAR-T cells. The therapy involves harvesting the patient’s own defense cells (T lymphocytes), modifying them in the laboratory to make them capable of destroying tumor cells, and reinjecting them into the body. These refractory cases usually relapse after conventional immunotherapy.
Leave A Comment